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Background: Familial hypercholesterolemia (FH) is an autosomal dominant disease caused by mutations in
the genes coding for the low density lipoprotein receptor (LDLR), proprotein convertase subtilisin/kexin
type-9 (PCSK9) or apo-lipoprotein B-100 (APOB). The aim of the present work was to determine the genetic
basis of dyslipidemia in 11 unrelated Pakistani families.
Methods: High resolution melting (HRM), sequencing and restriction fragment length polymorphism (RFLP).
Results: Probands were screened for the promoter and all coding regions, including intron/exon boundaries,
of LDLR and PCSK9 and part of exon 26 of APOB including p.(R3527Q). Two families were identiﬁed with pre-
viously unreported LDLRmutations (c.1019_1020delinsTG, p.(C340L) and c.1634G>A, p.(G545E)). Both pro-
bands had tendon xanthomas or xanthelasma and/or a history of cardiovascular disease. Co-segregation with
hypercholesterolemia was demonstrated in both families. In silico studies predicted these variations to be
damaging. In two families, novel PCSK9 variations were identiﬁed (exon2; c.314G>A, p.(R105Q) and
exon3; c.464C>T, p.(P155L)). In silico studies suggested both were likely to be damaging, and family mem-
bers carrying the p.(105Q) allele had lower total cholesterol levels, suggesting this is a loss-of-function mu-
tation. For c.464C>T p.(P155L) the small number of relatives available precluded any strong inference.
Conclusion: This report brings to seven the number of different LDLR mutations reported in FH patients from
Pakistan and, as expected in this heterogeneous population, no common LDLR mutation has been identiﬁed.© 2013 Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
Familial hypercholesterolemia (FH) is a heterogeneous autosomal
dominant disorder caused by mutations in the genes for the low density
lipoprotein receptor (LDLR), apolipoprotein B (APOB) or proprotein
convertase subtilase/kexin type 9 (PCSK9). Heterozygotes occur in the
general populationwith a frequency of approximately 1 in 500, homozy-
gotes at 1 in a million [1]. At present more than 1000 variants have been
identiﬁed in the LDLR associated with FH and premature cardiovascular
disease [2]. LDLR, predominantly expressed in hepatocytes, is processed
through the rough endoplasmic reticulum (RER) and transported to the
outer membrane. Here, low density lipoprotein (LDL) particles bind to
the LDLR and undergo endocytosis. They are processed in the endosome
generating free LDL, which is degraded, while the LDLR is recycled back
to themembrane. Some of the LDLR is bound to PCSK9 before endocyto-
sis which leads to the degradation of the receptor in the endosome,
resulting in a decreased number of receptors available for membrane
presentation. Mutations reported in the LDLR are associated with a de-
crease in LDLR function, resulting in an increase in plasma LDL and
total cholesterol (TC), and greatly increased risk of premature coronaryphries).
-ND license. heart disease (CHD) which can be signiﬁcantly reduced by statin treat-
ment [3]. Mutations in APOB that disrupt binding of the LDL-C particle
to the LDLR also cause FH [4], but such mutations (chieﬂy p.(R3527Q))
are commonly found only in subjects of European origin [5,6]. Mutations
in PCSK9 that are gain-of-function increase LDLR degradation and cause a
severe form of FH [7], but interestingly loss-of-function variants have
also been reported that result in less LDLR degradation, and carriers of
these variants have lower plasma LDL-C levels [8,9].
The spectrum of LDLR mutations causing FH has been studied in
many different countries as this information is useful in devising the
most efﬁcient laboratory strategy for genetic testing. In genetically het-
erogeneous countries such as the UK, Italy or the Netherlands, there
are many different mutations found [10,11]. Some mutations are more
common, and may show geographical clustering [12]. By contrast, in
countries with a strong “founder effect,” such as South Africa, Finland
or even in Greece [13,14], only a few mutations explain the majority of
FH patients making genetic testing much easier. To date there have
been few studies examining the spectrum of LDLRmutations in FH fam-
ilies from Pakistan or the Indian subcontinent, although some patients
examined in UK studies originate from the subcontinent [15]. We have
previously reported the identiﬁcation of mutations in four different pa-
tients from Pakistan, two nonsense mutations, p.(Val806GlyfsX11) [16]
and p.(C296X) [17] and three missense mutations p.(R88S) [17],
Table 1
Characteristics of probands.
ID Age
(years)
Gender Total-C
mmol/l
LDL
mmol/l
TG
mmol/l
HDL
mmol/l
Clinical
status
HC23-1a 45 M 9.78 5.74 3.04 1.47
HC26-2 52 F 6.31 3.90 0.90 1.84
HC27-1a 36 M 7.34 5.20 2.62 1.22
HC29-1 54 M 3.23 2.15 1.02 0.78 CABG
HC30-2a 23 M 6.54 5.84 1.97 1.19
HC32-2 65 M 6.34 4.34 1.43 1.16 MI
HC33-4 34 M 6.62 4.53 2.21 0.98
HC34-13a 35 F 8.84 6.00 2.31 1.76
HC35-1a 41 M 8.53 6.72 1.56 1.03 Xanthelasma
HC36-5 30 M 6.34 4.27 2.25 1.03
HC39-7a 2 M 24.18 22.08 2.31 1.03 Tendon
xanthoma
a Subjects with a Simon Broome clinical diagnosis of possible or deﬁnite FH.
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Here we extend the study to 11 additional probands and their extended
families. Of these, six had LDL-C levels above the UK cut-off for a clinical
diagnosis of FH of 4.9 mmol/l but, because there are no validated LDL-C
cut-offs for the clinical diagnosis of FH in Pakistan, we included 4 pro-
bands with LDL-C above 3.9 mmol/l, and one with premature CAD but
no elevation of plasma lipid levels.
2. Methods
2.1. Blood sampling and DNA extraction
The current studywas approved by the Ethics Committee and Institu-
tional ReviewBoard of Shifa College ofMedicine, Shifa International Hos-
pital, Islamabad. Six patients were identiﬁed based on the UK Simon
Broome criteria, including an elevated level of TC (>4.9 mmol/l) and de-
velopment of xanthomas or xanthelasma. Four probands had LDL-C
levels below this cut off (≥3.9 mmol/l) and one was included on the
basis of early cardiovascular diseases (HC29-1) although their lipid levels
were not elevated (Table 1). Bloodwas obtained from the subjects by ve-
nipuncture after obtaining informed written consent from the patient or
their representative. DNA was extracted from the lymphocytes using a
standard organic method as described elsewhere [19].
2.2. High resolution melting (HRM)
All the coding regions including the intron–exon boundaries and
the promoter (to c.-298) of the LDLR, exon 2 to 12 of PCSK9 and
part of exon 26 of APOB including p.R3527, were screened by HRM
and those samples with a shift in melting temperature were se-
quenced. Exon 1 and the promoter region of PCSK9 were screenedFig. 1. HRM proﬁles and sequencing of the variations found in LDLR and PCSK9.
A) HRM and sequencing of exon7 of the LDLR gene in family HC39 showing the double
within the family indicating that they are on the same allele.
a) HRM. Exon7 has a common polymorphism (c.1060+10G>). The shifts for the di
and HC39-7 which was found to be homozygous for the mutation.
b) Sequencing. The wild type sequence is shown in the upper panel and the heteroz
bases are indicated by arrows.
B) HRM and sequencing of exon2 of the PCSK9 gene in family HC29 showing the base c
a) HRM.The wild type and the shift in the two HC29 individuals are indicated, both
b) Sequencing.The wild type sequence is shown in the upper panel and the heterozyg
C) HRM and sequencing of exon3 of the PCSK9 gene in family HC26 showing the base c
a) HRM.The wild type and the shift in the individual HC26-2, heterozygous for the
b) Sequencing.The wild type sequence is shown in the upper panel and the heterozyg
D) HRM and sequencing of exon3 of the PCSK9 gene in family HC26 showing the base
a) HRM.The wild type and the shift in the individual HC26-2; heterozygous for the
b) Sequencing.The wild type sequence is shown in the upper panel and the heterozygby sequencing alone; this region contains several common polymor-
phisms making HRM results difﬁcult to analyze.
HRM was performed in the Rotorgene 6000 using AccuMelt HRM
SuperMix (Quanta Biosciences, Gaithersburg, Maryland, USA) with
60 ng of gDNA and 8 pmol of each primer in a ﬁnal volume of 20 μl or
the LightScanner High Sensitivity Master Mix (Idaho Technology Inc.
Utah, USA) with 30 ng of genomic DNA and 4 pmol of each primer in
a ﬁnal volume of 10 μl, according to the manufacturer's instructions.
The primers and PCR conditions used for the LDLR, APOB and PCSK9
genes are given in Supplementary Table 1.
2.3. Restriction fragment length polymorphism (RFLP)
The LDLR has several common polymorphisms (Supplementary
Table 2), which result in an HRM shift which is similar to that caused
by a mutation. To overcome this, samples were genotyped for common
polymorphisms by RFLP and their genotypes compared with the HRM
result. Those with shifts due to the polymorphism were not examined
further. However, variants of samples without the polymorphism but
with a shift were sequenced to ﬁnd the cause of the shift.
RFLPwas also used to screen the families of probands with potential
mutations to determine segregation of the variant with the FH pheno-
type (Supplementary Table 2). Polymerase chain reaction (PCR) ampli-
ﬁcation was carried out using 60 ng of gDNA, 2 mM Mg2+, 8 pmol of
each primer, and 0.4U of TaqDNA polymerase (Invitrogen) with the ap-
propriate 1× buffer in a ﬁnal volume of 20 μl. The PCR was performed
on a G-Storm thermal cycler (GRI) at 95 °C/3 min followed by 30 cycles
of 95 °C/30 s; 60 °C/30 s (except for primers of exon 2 of LDLR which
were annealed at 57 °C); 72 °C/30 s and a ﬁnal step of 72 °C/5 min.
Primers used for ampliﬁcation were the same as those used for HRM
(Supplementary Table 1). The ampliﬁed products were then digested
with the appropriate restriction enzyme (NEB (UK) Ltd., Hitchin,
Herts) using 8 μl of PCR product and 3U of the appropriate enzyme
(Supplementary Table 2) in a total volume of 13 μl and run on a 2% aga-
rose gel in 1×TBE buffer.
2.4. Sequence analysis
The samples for sequencing were ampliﬁed using the same primers
used for HRM (Supplementary Table 1) using the conditions above. The
ampliﬁed products were puriﬁed using GFX columns (GE Healthcare)
and sent to Source BioScience LifeSciences for sequencing.
2.5. Multiplex ligation-dependent probe ampliﬁcation (MLPA)
For screening gross rearrangements within the LDLR, Multiplex
Ligation-dependent Probe Ampliﬁcation (MLPA; Kit P062, MRC-Holland,base change TG>GC (c.1019_1020delinsGC (p.C340L)). The two changes co-segregate
fferent genotypes are indicated together with HC39-6; heterozygous for the mutation,
ygous (HC39-6) sequence for the double base change in the bottom panel. The relevant
hange G>A (c.314G>A (p.R105Q)).
are heterozygous for the mutation.
ous (HC29-1) sequence in the bottom panel. The relevant bases are indicated by arrows.
hange C>T (c.464C>T (p.P155L)).
mutation, are indicated.
ous (HC26-2) sequence in the bottom panel. The relevant bases are indicated by arrows.
change C>T (c.464C>T (p.P155L)).
mutation, are indicated.
ous (HC26-2) sequence in the bottom panel. The relevant bases are indicated by arrows.
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Fig. 2. Co-segregation of LDL-C levels with the mutations found in the families' of the probands. A) Family HC39 with LDLR Exon 7 c.1019_1020delinsTG, p.(C340L). B) Family HC35
with LDLR Exon11 c.1634G>A, p.(G545E) where each paired symbol (*, +, #, ) represents the same person. C) Family HC29 with PCSK9 Exon 2 c.314G>A p.(R105Q). D) Family
HC26 with PCSK9 Exon 3 c.464C>T p.(P155L). A double line between individuals indicates consanguinity. Probands are indicated by arrows, nk; not known.
222 W. Ahmed et al. / Clinica Chimica Acta 421 (2013) 219–225Amsterdam, The Netherlands) was used. Analysis was performed on all
probands following the manufacturer's instructions.
2.6. In silico analysis
In order to predict the possible impact of a variation on the function
of LDLR or PCSK9 the online tools Polyphen 2 (http://genetics.bwh.
harvard.edu/pph2/) [20] and SIFT (http://sift.jcvi.org/www/SIFT_enst_
submit.html) [21] were used.
3. Results
In the current study 11 familieswith FH and/ormyocardial infarction
(MI) were screened for possible mutations in LDLR, APOB and PCSK9
causing hyper- or hypo-cholesterolemia. The mean TC of the probands
was 8.36 ± 1.4 mmol/l, triglycerides 2.71 ± 0.47 mmol/l, high density
lipoprotein-cholesterol (HDL-C) 2.19 ± 0.52 mmol/l and LDL-C 5.07 ±
1.6 mmol/l. The sequencing of selected individuals identiﬁed by HRM
resulted in the identiﬁcation of two novel variants in LDLR and two
novel variants in PCSK9 in four different families (Fig. 1).
4. LDLR variations
In family HC39 the proband (VI-1) was found to be homozygous
for the mutation c.1019_1020delinsTG, p.(C340L) and had an ex-
tremely high total cholesterol of 24.2 mmol/l. His mother and father
were heterozygous for this mutation and the mother had a corre-
spondingly lower total cholesterol (10.6 mmol/l). The father's choles-
terol level was unavailable. Both the proband's paternal grandmotherand paternal uncle also had signiﬁcantly elevated total cholesterol
levels and were tested (by RFLP, data not shown) and found to be car-
riers of the mutation (Fig. 2A). As shown in Fig. 3A cysteine at amino
acid position 340 is highly conserved among vertebrates, from zebra
ﬁsh to mammals. Both SIFT and Polyphen2 predict this variant as
probably damaging.
In family HC35, the proband (HC35-1; IV-8) was heterozygous for
the variation c.1634G>A, p.(G545E) and had a total cholesterol level
of 8.5 mmol/l, while the three family members homozygous for this
mutation had average total cholesterol levels of 11.4 mmol/l. Most of
the patients from family HC35 were not on regular statin treatment
(Fig. 2B). The increase in LDL-C levels of the family members with or
without themutation and age are shown in Fig. 4A.While there was es-
sentially no increase with age in non-carriers there was a signiﬁcant
increase in carriers. Overall mean total cholesterol levels were signiﬁ-
cantly higher in carriers compared to non-carriers (6.9 mmol/l vs.
4.1 mmol/l p = 2.6E-07). As shown in Fig. 3B, the glycine residue at
this position is highly conserved in different species except zebra ﬁsh,
which has a serine at this position. Both SIFT and Polyphen2 predict
this variant as probably damaging.5. PCSK9 variations
In family HC29, the proband (III-2) (Fig. 2C) was heterozygous for
c.314G>A, p.(R105Q) with a total cholesterol level of 3.21 mmol/l,
but with premature CHD. Individuals heterozygous for this variant
had a mean total cholesterol level of 3.19 mmol/l as compared to
the non-carriers with an average total cholesterol of 3.93 mmol/l
(p = 0.8). The proband (III-2) and his brother (III-3) had undergone
Fig. 3. Conservation of amino acid residues in different species. A) LDLR Exon 7 c.1019_1020delinsTG, (p.C340L) found in family HC39. B) LDLR Exon 11 c.1634G>A (p.G545E) found
in family HC35. C) PCSK9 Exon 2 c.314G>A (p.R105Q) found in family HC29 D) PCSK9 Exon 3 c.464C>T (p.P155L) found in family HC26.
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respectively, while one of their offspring (IV-3) had left anterior de-
scending artery (LAD) stenting at the age of 21 years. As shown in
Fig. 4B cholesterol levels rise with age, in both carriers and non-
carriers, but the average level in carriers appears lower although
this does not reach statistical signiﬁcance. As shown in Fig. 3C, the ar-
ginine residue at this position is not highly conserved in different spe-
cies although it is only substituted by lysine which is a similarly
charged residue. Polyphen predicts this variant to be damaging
whereas SIFT predicts that this variation will be tolerated.
In the family HC26, the proband (III-3) (Fig. 2D)was found to be het-
erozygous for c.464C>T p.(P155L) with a total cholesterol level of
6.34 mmol/l. Mean total cholesterol levels were only available for two
of the three carriers in this family; mean (SD) in carriers is 5.20 mmol/l
(1.56) compared to 4.77 mmol/l (1.34) in seven non-carriers (p =
0.71). As shown in Fig. 3D, the proline residue at this position is con-
served in all species, and both SIFT and Polyphen2 predict this variant
as damaging. However this variant did not show strong evidence for
co-segregation with lipid levels in this small family (Fig. 4C).
6. Discussion
In order to develop the most efﬁcient genetic testing approach for
patients with FH, there is a need to deﬁne all the pathogenic variants
in the LDLR gene in different populations. Pakistan is a multi-racial
nation and therefore this heterogeneous population is expected to
carry a number of novel LDLR mutations. To date ﬁve different muta-
tions in Pakistani FH patients have been reported [16–18]. Among the
families in the current study two additional novel mutations were
identiﬁed in two different families. All except one of the probands
screened here had hypercholesterolemia (mean total cholesterol in
Pakistan reported to be 4.5 mmol/l [22]), and although only six had
LDL-C levels above the UK cut-off for a clinical diagnosis of FH
(>4.9 mmol/l), because there are no validated LDL-C cut-offs for the
clinical diagnosis of FH in Pakistan, we included 4 probands with
LDL-C above 3.9 mmol/l, and one with premature CAD but no eleva-
tion of plasma lipid levels. After excluding this subject, the mutation
detection rate of 2/10 (20%) in this sample of patients is lower than
previously reported for deﬁnite FH patients but is similar to the
20-30% reported in possible FH patients in the UK [14]. The presenceof tendon xanthomas is the major diagnostic criterion for deﬁnite as
opposed to possible FH [1] and only one of the probands had tendon
xanthomas (HC39-7).
In family HC39, the LDLR mutation p.(C340L) was found in a ho-
mozygous 2 year old child with xanthomas, while his mother was
heterozygous for this change. This change lies in exon 7 of the LDLR
which encodes part of the epidermal growth factor (EGF) like region
of the LDLR. This cysteine residue is highly conserved among verte-
brates, from zebra ﬁsh to mammals, indicating its important role in
the function (Fig. 3A) of this region. Although this cysteine residue
is not in the seven cysteine repeats important for the binding of
LDL-C to the receptor, it is a part of the EGF like 1 domain involved
in the displacement of LDL-C in the acidic environment of the endo-
some [23]. In family HC35, the mutation p.(G545E) was observed in
the heterozygous proband with LDL-C level of 6.8 mmol/l, while
three individuals of family HC35 were homozygous for the mutant al-
lele. The glycine residue at this position is highly conserved in differ-
ent species except zebra ﬁsh, which has a serine at this position
(Fig. 3B). Both SIFT and Polyphen2 predict this variant as damaging.
In Family HC35, there were enough carriers and non-carriers to
compare the rate of increase in LDL-C levels with increasing age.
Compared to the non-carriers, where there was no evidence of an
age effect, mean levels were higher in older compared to younger car-
riers. While this cross-sectional data has limitations, it suggests that
the impact of the LDLR defect on LDL clearance may be seen most
clearly in individuals where age-related effects on plasma lipid me-
tabolism places the system under metabolic stress.
Two potentially pathogenic variants in PCSK9 were identiﬁed,
p.(R105Q) and p.(P155L), located in the pro-domain and autocatalyt-
ic domain of PCSK9 respectively. Interestingly, carriers of p.(R105Q)
had 19% lower total cholesterol levels compared to non-carriers in
family HC29, with the lower cholesterol levels being apparent in indi-
viduals of different ages. This suggest p.(R105Q) is a loss-of-function
variant not a gain-of-function FH-causing mutation. This variant is in
the pro-domain of PCSK9, the autocatalytic domain does not start
until aa153, so it is not clear what the molecular mechanism of this
variant would be. More than an 80% decrease in autocatalytic activity
has been reported due to mutations in the pro-segment of PCSK9
[24,25] and, if this is the mechanism, the number of LDLR on hepato-
cytes would be higher, which would increase the uptake of circulating
Fig. 4. The increase in LDL-C levels of family members with age with or without a mutation. A) Family HC35 LDL-C levels with or without LDLRmutation p.(G454E). B) Family HC29
LDL-C levels with or without PCSK9 mutation p.(R105Q). C) Family HC26 LDL-C levels with or without PCSK9 mutation p.(P155L). Probands are indicated by arrows.
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et al. [23] reported 32% more LDLR on the cell surface in p.(G106R)
mutants of PCSK9 compared to the wild-type PCSK9, with 71% in-
creased LDL-C clearance through internalization leading to lowering
of LDL-C in the serum. The in silico predictions that this variant
would be probably damaging support this.
The effect of the p.(P155L) PCSK9 variant detected is less clear cut.
Mayne et al. [26] reported a loss of function mutation p.(Q152H) in
PCSK9, in a French Canadian family. This variant is near the autocatalytic
site which is cleaved by the enzyme SIP at p.Q152, with the variant al-
lele, p.(152H), not undergoing efﬁcient autocatalytic cleavage, resulting
in a 79% decrease in serum levels of PCSK9 and up to 48% lowering of TC
among the carriers. Benjannet et al. [24] reported that the proline resi-
due at position 155 in the catalytic site is important for autocatalytic
activity, presumably because the β-turn following this residue isimportant for the cleavage and subsequent release of mature PCSK9
from the endoplasmic reticulum. In support of this the in silico analysis
suggests that this variant will be damaging, but this cannot be used to
infer whether this would be a loss or gain of function effect. Unfortu-
nately the family HC26 is too small to give a clear answer. LDL-C levels
were not signiﬁcantly different in the carriers compared to non-carriers,
and extending the family by tracing further relatives would be useful.
In conclusion, we have identiﬁed two additional novel mutations in
LDLR in FH patients from Pakistan, bringing the total number identiﬁed
to date to seven. All of these mutations occur in only one family, al-
though the sample of patients examined to date is too small to be able
to say whether or not any may be common. None of these mutations
have been identiﬁed in FH patients from the Indian subcontinent living
in the UK [14], suggesting that the genetic heterogeneity in the subcon-
tinent is likely to be considerable. It is unclear whether the patients
225W. Ahmed et al. / Clinica Chimica Acta 421 (2013) 219–225where no mutation could be found have a mutation in a region of the
LDLR gene not examined here, or that they may have a mutation in a
yet to be discovered gene or, perhaps most likely, that they do not
have monogenic FH. Further family studies may help to distinguish
these difﬁculties. The current study highlights the beneﬁts of a deﬁni-
tive DNA-based diagnosis for FH families where, based upon this genet-
ic data, better counselling and a better choice of future treatments is
available. For the mode of action of the PCSK9 variants in decreasing
LDL-C levels, further functional studies will enhance our knowledge
and may be helpful in devising novel therapeutics.
Acknowledgement
Thisworkwasﬁnancially supported by grant no. 934 from theHigher
Education Commission of Pakistan, awarded to R.Q. Part of thisworkwas
supported by Shifa College of Medicine through a core grant to R.Q.W.A.
was supported by an IRSIP grant from HEC for his studies at UCL. We
would like to thank the FH families and healthy individuals for donating
their blood. S.E.H., R.W. and W.P. are supported by the British Heart
Foundation (RG008/08).
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.cca.2013.03.017.
References
[1] Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural
history, and treatment of familial hypercholesterolaemia. Atherosclerosis
2003;168:1–14.
[2] Leigh SE, Foster AH, Whittall RA, Hubbart CS, Humphries SE. Update and analysis
of the University College London low density lipoprotein receptor familial hyper-
cholesterolemia database. Ann Hum Genet 2008;72:485–98.
[3] Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, et al. Reductions in
all-cause, cancer, and coronary mortality in statin-treated patients with heterozy-
gous familial hypercholesterolaemia: a prospective registry study. Eur Heart J
2008;29:2625–33.
[4] Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hy-
percholesterolemia. Nat Clin Pract Cardiovasc Med 2007;4:214–25.
[5] Dušková L, Kopečková L, Jansová E, Tichý L, Freiberger T, Zapletalová P, et al. An
APEX-based genotyping microarray for the screening of 168 mutations associated
with familial hypercholesterolemia. Atherosclerosis 2011;216:139–45.
[6] Liyanage KE, Burnett JR, Hooper AJ, van Bockxmeer FM. Familial hypercholesterol-
emia: epidemiology, Neolithic origins and modern geographic distribution. Crit
Rev Clin Lab Sci 2011;48:1–18.
[7] Naoumova RP, Tosi I, Patel D, Neuwirth C, Horswell SD, Marais AD, et al. Severe
hypercholesterolemia in four British families with the D374Y mutation in the
PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb
Vasc Biol 2005;25:2654–60.
[8] Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL
cholesterol in individuals of African descent resulting from frequent nonsense
mutations in PCSK9. Nat Genet 2005;37:161–5.[9] Scartezini M, Hubbart C, Whittall RA, Cooper JA, Neil AH, Humphries SE. The
PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardio-
vascular risk in healthy U.K. men. Clin Sci (Lond) 2007;113:435–41.
[10] Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar AK, et al.
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to
plasma lipid levels and coronary heart disease risk. J Med Genet 2006;43:943–9.
[11] Romano M, Di Taranto MD, D'Agostino MN, Marotta G, Gentile M, Abate G, et al.
Identiﬁcation and functional characterization of LDLR mutations in familial hy-
percholesterolemia patients from Southern Italy. Atherosclerosis 2010;210:
493–6.
[12] Kusters DM, Huijgen R, Defesche JC, Vissers MN, Kindt I, Hutten BA, et al. Founder
mutations in the Netherlands: geographical distribution of the most prevalent
mutations in the low-density lipoprotein receptor and apolipoprotein B genes.
Neth Heart J 2011;19:175–82.
[13] Traeger-Synodinos J, Mavroidis N, Kanavakis E, Drogari E, Humphries SE, Day IN,
et al. Analysis of low density lipoprotein receptor gene mutations and microsatel-
lite haplotypes in Greek FH heterozygous children: six independent ancestors ac-
count for 60% of probands. Hum Genet 1998;102:343–7.
[14] Miltiadous G, Elisaf M, Bairaktari H, Xenophontos SL, Manoli P, Cariolou MA. Char-
acterization and geographic distribution of the low density lipoprotein receptor
(LDLR) gene mutations in northwestern Greece. Hum Mutat 2001;17:432–3.
[15] Taylor A, Wang D, Patel K, Whittall R, Wood G, Farrer M, et al. Mutation detection
rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cas-
cade project. Clin Genet 2010;77:572–80.
[16] Ajmal M, Ahmed W, Sadeque A, et al. Identiﬁcation of a recurrent insertion muta-
tion in the LDLR gene in a Pakistani family with autosomal dominant hypercho-
lesterolemia. Mol Biol Rep 2010;37:3869–75.
[17] AjmalM, AhmedW, Akhtar N, Sadeque A, Khalid A, Benish Ali SH, et al. A novel path-
ogenic nonsense triple-nucleotide mutation in the low-density lipoprotein receptor
gene and its clinical correlation with familial hypercholesterolemia. Genet Test Mol
Biomarkers 2011;15:601–6.
[18] Ahmed W, Ajmal M, Sadeque A, Whittall RA, Raﬁq S, Putt W, et al. Novel and re-
current LDLR gene mutations in Pakistani hypercholesterolemia patients. Mol Biol
Rep 2012;39:7365–72.
[19] Sambrook J. Molecular cloning: a laboratory manual. 3rd ed.Cold Spring Harbor,
N.Y.: Cold Spring Harbor Laboratory Press; 2001
[20] Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A
method and server for predicting damaging missense mutations. Nat Methods
2010;7:248–9.
[21] Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous var-
iants on protein function using the SIFT algorithm. Nat Protoc 2009;4:1073–81.
[22] Ahmed W, Malik M, Saeed I, Khan AA, Sadeque A, Kaleem U, et al. Role of tissue
plasminogen activator and plasminogen activator inhibitor polymorphism in
myocardial infarction. Mol Biol Rep 2011;38:2541–8.
[23] Innerarity TL. Structural biology. LDL receptor's beta-propeller displaces LDL. Sci-
ence 2002;298:2337–9.
[24] Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, et al.
NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the
low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem
2004;279:48865–75.
[25] Cameron J, Holla OL, Ranheim T, Kulseth MA, Berge KE, Leren TP. Effect of muta-
tions in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet
2006;15:1551–8.
[26] Mayne J, Dewpura T, Raymond A, Bernier L, Cousins M, Ooi TC, et al. Novel
loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in
a French–Canadian family and with impaired processing and secretion in cell cul-
ture. Clin Chem 2011;57:1415–23.
